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 Breast cancer is a molecularly heterogeneous disease that appears to 
include at least four major tumor subtypes ( 1 – 3 ). Currently, the 
choice of adjuvant systemic therapy is based on patient ’ s age, tumor 
size, histological grade, lymph node involvement, hormone receptor 
status, and HER2 status. The only predictive markers with an asso-
ciated targeted therapy are the estrogen receptor (ER) and HER2. 
The approximately 15% of patients with breast cancer who have 
HER2 overexpressing and/or amplified tumors are treated with a 
combination of trastuzumab, a monoclonal antibody targeting 
HER2, and adjuvant chemotherapy ( 4 ). For the two-thirds of breast 
cancers that are positive for ER and/or progesterone receptor (PR), 
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  Background  Gene expression profiling of breast cancer has identified two biologically distinct estrogen receptor (ER)-
positive subtypes of breast cancer: luminal A and luminal B. Luminal B tumors have higher proliferation 
and poorer prognosis than luminal A tumors. In this study, we developed a clinically practical immunohis-
tochemistry assay to distinguish luminal B from luminal A tumors and investigated its ability to separate 
tumors according to breast cancer recurrence-free and disease-specific survival. 
  Methods  Tumors from a cohort of 357 patients with invasive breast carcinomas were subtyped by gene expression 
profile. Hormone receptor status, HER2 status, and the Ki67 index (percentage of Ki67-positive cancer 
nuclei) were determined immunohistochemically. Receiver operating characteristic curves were used to 
determine the Ki67 cut point to distinguish luminal B from luminal A tumors. The prognostic value of the 
immunohistochemical assignment for breast cancer recurrence-free and disease-specific survival was 
investigated with an independent tissue microarray series of 4046 breast cancers by use of Kaplan – Meier 
curves and multivariable Cox regression. 
  Results  Gene expression profiling classified 101 (28%) of the 357 tumors as luminal A and 69 (19%) as luminal B. 
The best Ki67 index cut point to distinguish luminal B from luminal A tumors was 13.25%. In an indepen-
dent cohort of 4046 patients with breast cancer, 2847 had hormone receptor – positive tumors. When HER2 
immunohistochemistry and the Ki67 index were used to subtype these 2847 tumors, we classified 1530 
(59%, 95% confidence interval [CI] = 57% to 61%) as luminal A, 846 (33%, 95% CI = 31% to 34%) as luminal 
B, and 222 (9%, 95% CI = 7% to 10%) as luminal – HER2 positive. Luminal B and luminal – HER2-positive 
breast cancers were statistically significantly associated with poor breast cancer recurrence-free and 
disease-specific survival in all adjuvant systemic treatment categories. Of particular relevance are women 
who received tamoxifen as their sole adjuvant systemic therapy, among whom the 10-year breast cancer – 
specific survival was 79% (95% CI = 76% to 83%) for luminal A, 64% (95% CI = 59% to 70%) for luminal B, 
and 57% (95% CI = 47% to 69%) for luminal – HER2 subtypes. 
  Conclusion  Expression of ER, progesterone receptor, and HER2 proteins and the Ki67 index appear to distinguish 
luminal A from luminal B breast cancer subtypes. 
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endocrine therapy with tamoxifen ( 5 ) or aromatase inhibitors ( 6 , 7 ) 
is generally indicated. The application of adjuvant systemic therapy 
has contributed to a recent decrease in breast cancer mortality ( 8 ). 
When patients with hormone receptor – positive tumors were treated 
with adjuvant tamoxifen, their risk for the composite outcome of 
recurrence or death was reduced by more than 30% ( 8 ). However, 
many patients with lymph node – positive, ER-positive breast tumors 
gain minimal benefit from adjuvant chemotherapy ( 9 ). 
 Although adjuvant systemic therapy fails to prevent recurrence in 
some patients with high-risk hormone receptor – positive breast cancer, 
many lower risk patients may have been subjected to side effects with-
out beneﬁ t from such interventions. Thus, there is a need to distin-
guish patients with hormone receptor – positive tumors at high risk for 
recurrence despite current treatment protocols from patients at low 
risk for whom adjuvant hormonal therapy alone may be sufﬁ cient. 
 Breast cancers expressing high levels of Ki67, a nuclear marker 
of cell proliferation, are associated with worse outcomes ( 10 – 12 ). 
Ki67 is not included in routine clinical decision-making because of 
a lack of clarity regarding how Ki67 measurements should inﬂ u-
ence clinical decisions. Recent studies ( 13 , 14 ) indicate that changes 
in Ki67 expression after neoadjuvant endocrine treatment may 
predict long-term outcome. 
 Gene expression studies have identiﬁ ed ﬁ ve molecularly distinct 
subtypes of breast cancer that have prognostic value across multiple 
treatment settings ( 3 , 15 – 17 ). These subtypes are termed ER-positive –
 luminal A (luminal A), ER-positive – luminal B (luminal B), HER2-
enriched (ie, tumors that overexpress ERBB2-associated genes but do 
not express genes that deﬁ ne the luminal subtype), basal-like, and 
normal breast-like. HER2-enriched and basal-like subtypes are hor-
mone receptor negative and have poor prognosis ( 1 – 3 ). In contrast, 
the expression of ER-associated genes characterizes the luminal breast 
cancers, with luminal B tumors having poorer outcomes than luminal 
A tumors. Although some luminal B tumors can be identiﬁ ed by their 
expression of HER2, the major biological distinction between luminal 
A and B is the proliferation signature, including genes such as  CCNB1 , 
 MKI67 , and  MYBL2 , which have higher expression in luminal B 
tumors than in luminal A tumors ( 15 , 18 ). The recurrence score ( 19 ), 
which is derived from quantitative reverse transcription – polymerase 
chain reaction (qRT-PCR) assays of the expression of 16 discrimina-
tor genes, divides ER-positive, lymph node – negative tumors into 
prognostic subgroups. The expression of genes that are involved in 
proliferation, including  MKI67 (encoding Ki67), is the most heavily 
weighted component in calculating the recurrence score derived from 
that assay. Thus, a distinction between luminal A and B tumors that 
is based on proliferation status among ER-positive luminal patients 
may be important to breast cancer biology and prognosis. 
 The high cost of gene expression proﬁ ling has limited its incorpo-
ration into most randomized clinical trials, and therefore, DNA 
microarray – deﬁ ned proliferation status is not used to provide prog-
nostic information in general practice. To date, there is no available 
immunohistochemistry-based surrogate assay that can distinguish 
between luminal A and luminal B tumors. However, our previously 
deﬁ ned immunohistochemistry surrogate for identifying the basal-like 
subtype ( 20 , 21 ), which includes ER, PR, and HER2 status, does iden-
tify hormone receptor – positive, HER2-positive patients as having a 
worse outcome. To further facilitate proliferation measures by immu-
nohistochemistry, technically excellent rabbit monoclonal antibodies 
for Ki67 are now available ( 22 ), and thus, the Ki67 labeling index may 
serve as a clinically valuable biomarker for the luminal B subtype. 
 Consequently, we sought to determine 1) the optimal cut point for 
the percentage of Ki67-positive invasive breast cancer cells that would 
distinguish between luminal A and luminal B tumors, by comparing 
gene expression proﬁ le assignments and immunohistochemistry data 
from formalin-ﬁ xed parafﬁ n-embedded tissues; 2) the prognostic 
value of the Ki67 index (percentage of invasive cancer cell nuclei that 
are positive for Ki67 immunostaining over total invasive cancer cell 
nuclei present in a histological sample) among hormone receptor – 
positive tumors from a large independent series of patients who had 
not received adjuvant systemic therapy; and 3) the association between 
the Ki67 index and outcome among patients with hormone receptor – 
positive tumors who were treated with tamoxifen as their sole adjuvant 
systemic therapy. We tested the hypothesis that the immunohis-
tochemical determination of ER, PR, and HER2 status and the Ki67 
index is able to distinguish the poor prognosis luminal B subgroup of 
breast cancers from the good prognosis luminal A subgroup. 
 Patients, Materials, and Methods 
 Cohorts of Patients 
 The training set contained a total of 357 formalin-fixed paraffin-
embedded tissues from invasive breast carcinomas from the 
 CONTEXT AND CAVEATS 
 Prior knowledge 
 Two biologically distinct estrogen receptor – positive subtypes of 
breast cancer have been identified by gene expression profiling of 
breast cancers: luminal A and luminal B, with luminal B tumors 
having a higher rate of tumor cell proliferation and poorer progno-
sis than luminal A tumors. 
 Study design 
 A group of tumors from patients with invasive cancer was sub-
jected to gene expression profiling to determine the breast cancer 
subtype. Another group of hormone receptor – positive breast can-
cers was assessed by immunohistochemistry for the expression of 
a panel of four biomarkers for breast cancer (ie, estrogen receptor, 
progesterone receptor, HER2, and Ki67); patients in this group 
were separated by subtype determined by immunohistochemistry, 
and their survival was analyzed. 
 Contribution 
 Luminal A and B breast cancers appear to be distinguished by the 
expression of estrogen receptor, progesterone receptor, HER2, and 
Ki67 proteins. 
 Implications 
 An immunohistochemistry test of four biomarkers appears to be able 
to separate breast cancer patients by subtype. Additional research is 
warranted to determine whether this assay could have clinical utility. 
 Limitations 
 This study has limitations typical of immunohistochemical 
approaches, including limited technical reproducibility, subjective 
interpretation, and qualitative readouts. The false-positive and 
false-negative rates of the assay were approximately 25%. 
 From the Editors 
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University of British Columbia and Washington University at 
St Louis (hereafter referred to as the UBC-WashU series). This 
series was chosen to include high- and low-risk patient groups, so 
that each of the major intrinsic breast cancer subtypes was repre-
sented by adequate numbers of specimens. In the combined cohort 
of 357 tumors, 137 (38%) were from patients with lymph node – 
positive disease, 200 (56%) were larger than 2 cm in diameter, and 
133 (37%) were grade 3 by the Bloom and Richardson method ( 23 ) 
( see  Table 1 ). 
 The validation set contained a total of 4046 formalin-ﬁ xed 
parafﬁ n-embedded tissues. All patients had been referred to the 
British Columbia Cancer Agency from January 1, 1986, through 
September 30, 1992, and had staging, pathology, treatment, and 
follow-up information available ( see  Table 1 ); this cohort is hereaf-
ter referred to as the BCCA series. The median follow-up time was 
12.5 years. In British Columbia, most patients were treated with 
adjuvant systemic therapy according to provincial cancer manage-
ment guidelines set by the British Columbia Cancer Agency ( 24 ). 
The guidelines provided criteria for deﬁ ning high-risk patients 
who could beneﬁ t from adjuvant systemic therapy. A high-risk 
patient was deﬁ ned as being lymph node positive, having lympho-
vascular invasion, or having a tumor larger than 2 cm in diameter 
if it was also ER negative. Patients who were considered to be at 
clinically low risk at the time of diagnosis during the study era, 
which included approximately 40% of the study cohort, were not 
recommended to receive any adjuvant systemic therapy. Patients 
who were considered to be at high risk were recommended to 
receive tamoxifen if their tumor was ER positive and if they were 
older than 65 years, to receive chemotherapy if their tumor was 
ER negative or if they were younger than 50 years, and to receive 
both if their tumor was ER positive and if they were between 
ages 50 and 65 years. 
 Biomarker studies on the anonymized archival specimens and 
clinical data were approved by the Clinical Research Ethics Board 
of the British Columbia Cancer Agency and the Human Research 
Protection Ofﬁ ce of Washington University. Tissues were col-
lected according to institutional  review board – approved protocols 
of the Alvin J. Siteman Cancer Center Tissue Procurement Core 
and at the British Columbia Cancer Agency. 
 In the BCCA series of 4046 breast tumors, a total of 2847 
tumors were hormone receptor positive, of which 2598 had com-
plete immunohistochemistry data for ER, PR, HER2, and Ki67 
( see  Table 1 ). We found no statistically signiﬁ cant differences in 
age, tumor size, lymph node status, or adjuvant systemic therapy 
between patients with complete immunohistochemistry data and 
patients with missing data; however, the missing data status was 
associated with less lymphovascular invasion ( P = .010) and with 
a marginal tendency for lower grade (grade 1 or 2 vs grade 3) 
( P = .048) compared with the complete data available status. 
 Gene Expression Profiling by qRT-PCR to Define Breast 
Cancer Subtypes 
 The 357 tumor samples in the UBC-WashU series were subjected 
to qRT-PCR. The strategy used to develop and implement a breast 
cancer specimen classifier is detailed in  Figure 1 . The 50-gene 
PAM50 subtype predictor, as described by Parker et al. ( 25 ), was 
used to assign intrinsic subtypes to each tumor specimen in the 
training set from gene expression profiles that had been generated 
by qRT-PCR. Total RNA was extracted from pathologist-guided 
core samples of the paraffin-embedded tissue blocks (two core 
punches, each 1.5 mm in diameter, taken from areas adjacent to the 
cores that were extracted for tissue microarrays) by use of a High 
Pure RNA Paraffin kit (Roche Applied Science, Indianapolis IN). 
After treatment with Turbo DNase (Ambion, Austin, TX), total 
RNA yield was assessed with the ND-1000 Spectrophotometer 
(NanoDrop Technologies, Rockland, DE). Gene expression by 
qRT-PCR was determined as described previously ( 25 , 26 ). In brief, 
first-strand cDNA was synthesized from 1.2  µ g of total RNA with 
Superscript III reverse transcriptase (First Strand Kit; Invitrogen, 
Carlsbad, CA) and a mixture of random hexamers and gene-specific 
primers. PCR amplification was carried out on 1.25 ng of the 
resulting cDNA in the presence of SYBRGreen I Master Mix 
(Roche Applied Science). Double-stranded DNA, which incorpo-
rated the SYBRGreen 530-nm fluorophore, was detected by use of 
the Roche LightCycler 480 (Roche Applied Science). Melting 
curve analysis was used to verify the specificity of the amplified 
products for each gene. The relative gene copy number was deter-
mined by following the manufacturer’s directions. PCR primers 
optimized for use on formalin-fixed paraffin-embedded materials 
were thereby used to make quantitative measurements for a panel 
of 50 discriminatory genes selected for the capacity to discriminate 
luminal A, luminal B, HER2-enriched, basal-like, and normal 
breast-like  expression profiles [the PAM50 bioclassifier panel, as 
described in detail in Parker et al. ( 25 )]. 
 Tissue Microarrays 
 Tissue microarrays were constructed, as described previously 
( 20 , 27 , 28 ), by use of the 4046 formalin-fixed paraffin-embedded 
archival blocks from the validation dataset. Slides from these 
blocks that were stained with hematoxylin – eosin were reviewed by 
two pathologists to identify areas of invasive breast cancer. Single 
0.6-mm cores were extracted from each tumor block to construct 
tissue microarrays. A total of 17 tissue array blocks were built to 
assemble the complete 4046 tumor series. 
 Immunohistochemistry and Fluorescent In Situ 
Hybridization 
 The 4046 tumors assembled into tissue microarrays, in BCCA 
series, were examined with immunohistochemistry and fluorescent 
in situ hybridization. Immunohistochemistry for ER, PR, HER2, 
and Ki67 was performed concurrently on serial sections with the 
standard streptavidin – biotin complex method with 3,3 ′ -
diaminobenzidine as the chromogen. Staining for ER, PR, and 
HER2 interpretation was as described previously ( 20 ). Briefly, the 
Ki67 antibody (clone SP6; ThermoScientific, Fremont, CA) was 
applied at a 1:200 dilution for 32 minutes, by following the 
Ventana Benchmark automated immunostainer (Ventana, Tucson 
AZ) standard Cell Conditioner 1 (CC1, a proprietary buffer) 
protocol at 98°C for 30 minutes. ER antibody (clone SP1; 
ThermoFisher Scientific, Fremont CA) was used at 1:250 dilution 
with 10-minute incubation, after an 8-minute microwave antigen 
retrieval in 10 mM sodium citrate (pH 6.0). Ready-to-use PR anti-
body (clone 1E2; Ventana) was used by following the CC1 proto-
col as above. HER2 staining was done with the SP3 antibody 
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(ThermoFisher Scientific) at a 1:100 dilution after antigen retrieval 
in 0.05 M Tris buffer (pH 10.0) with heating to 95°C in a steamer 
for 30 minutes. For HER2 fluorescent in situ hybridization assay, 
slides were hybridized with probes to LSI (locus-specific identifier) 
HER2/neu and to centromere 17 by use of the PathVysion HER-2 
DNA Probe kit (Abbott Molecular, Abbott Park, IL) according to 
manufacturer’s instructions, with modifications to pretreatment 
and hybridization as previously described ( 29 ). Slides were coun-
terstained with 4 ′ ,6-diamidino-2-phenylindole, stained material 
was visualized on a Zeiss Axioplan epifluorescent microscope, and 
signals were analyzed with a Metafer image acquisition system 
(Metasystems, Altlussheim, Germany). Biomarker expression from 
immunohistochemistry assays was scored by two surgical patholo-
gists (T. O. Nielsen and D. Gao), who were blinded to the clinico-
pathological characteristics and outcome and who used previously 
established and published criteria for biomarker expression levels 
that had been developed on other breast cancer cohorts ( 12 , 30 ). 
Tumors were considered positive for ER ( 27 ) or PR ( 31 ) if immu-
nostaining was observed in more than 1% of tumor nuclei, as 
described previously. Tumors were considered positive for HER2 
if immunostaining was scored as 3+ according to HercepTest cri-
teria, with an amplification ratio for fluorescent in situ hybridiza-
tion of 2.0 or more being the cut point that was used to segregate 
immunohistochemistry equivocal tumors (scored as 2+) ( 32 ). Ki67 
was visually scored for percentage of tumor cell nuclei with posi-
tive immunostaining above the background level by two patholo-
gists (T. O. Nielsen and D. Gao). Tissue microarray core samples 
with fewer than 50 tumor cells were considered uninterpretable 
( 27 , 28 ). All the stained tissue microarrays were digitally scanned, 
and primary image data are available for public access ( http://www.
gpecimage.ubc.ca ; username, luminalB; password, luminalb). 
 Statistical Analysis 
 All statistical analyses were carried out in SPSS version 16.0 (SPSS, 
Inc., Chicago, IL) and R version 2.6.0 ( www.r-project.org ). For 
breast cancer subtype prediction with qRT-PCR data, the 50-gene 
PAM50 classifier, as described in detail by Parker et al. ( 25 ), was 
used to assign breast cancer subtypes to the 357 training samples. 
The algorithm maps the gene expression in each specimen to cen-
troids (a multidimensional average expression of the 50 discrimina-
tory genes) that were previously constructed from prototypical 
examples of the five breast cancer subtypes (luminal A, luminal B, 
HER2-enriched, basal-like, and normal breast-like) ( 25 ). We 
assigned a subtype to each tumor specimen tested by calculating 
the distances to each of the subtype centroids with the Spearman 
rank correlation test. Tumors for which the difference between 
Spearman rank correlation coefficients for the luminal A and B 
centroids was less than 0.1 were considered borderline. 
 Expression of ER and ER-associated genes is a characteristic of 
luminal breast cancers as deﬁ ned by microarray expression proﬁ l-
ing ( 1 – 3 ). Approximately 30% of tumors in the luminal B cluster 
expressed HER2 and associated genes, and in this study, we 
deﬁ ned tumors that expressed hormone receptor proteins (ER or 
PR) and were positive for HER2 as being of the luminal – HER2-
positive subtype. However, the remaining 70% of luminal B 
tumors primarily differed from better prognosis luminal A tumors 
by virtue of higher expression of proliferation genes ( 15 , 18 ). We 
investigated whether addition of the proliferation marker Ki67 to 
the immunopanel of ER, PR, and HER2 could distinguish luminal 
B tumors (ie, hormone receptor – positive, HER2-negative, and 
Ki67-high tumors) from luminal A tumors (ie, hormone receptor – 
positive, HER2-negative, and Ki67-low tumors). In the UBC-
WashU series, we used the 50-gene PAM50 classiﬁ er to identify 
tumors as being either luminal A or luminal B, to determine the 
optimal cut-point value for the Ki67 index. We then compared 
quantitative data from visual assessment of Ki67 immunohis-
tochemical labeling against these gene expression proﬁ le – based 
assignments for hormone receptor – positive, HER2-negative 
tumors. The optimal cutoff value for Ki67 was selected by use of 
the receiver operating characteristic (ROC) method, by minimiz-
ing the sum of the observed false-positive and false-negative errors 
with bootstrapping methodology ( 33 ). In this fashion, the cutoff 
value was selected against the gold standard of gene expression 
proﬁ ling, as opposed to assigning a cut point against clinical out-
come (which can be difﬁ cult to extrapolate to other patient popula-
tions with differences in treatment and risk). 
 The immunopanel thereby deﬁ ned (ie, ER, PR, HER2, and 
Ki67) was used to assign tumors of the BCCA validation series to 
breast cancer subtypes and to assess clinicopathological character-
istics and the relation to patient outcome. We estimated 95% 
conﬁ dence intervals (CIs) with bootstrapping methodology ( 32 ) 
for the reported percentages of luminal subtypes as deﬁ ned by the 
immunopanel. Differences in clinicopathological characteristics, 
including age, tumor grade, tumor size, and lymph node status, 
among breast cancer subtypes were examined by use of   2 tests. 
For univariate survival analysis, relapse -free survival and breast 
cancer – speciﬁ c survival were estimated by use of Kaplan – Meier 
curves ( 34 ), and the statistical signiﬁ cance of survival differences 
was assessed with a log-rank test ( 35 ). For relapse-free survival, 
survival time was censored at death if the cause was not breast 
cancer or if the patient was alive without relapse on June 30, 2004. 
For breast cancer – speciﬁ c survival, survival time was censored at 
death if the cause was not breast cancer or if the patient was still 
alive on June 30, 2004 (the date for outcome data collection). 
Patients with unknown cause of death were excluded from breast 
cancer – speciﬁ c survival analysis. For multivariable survival analy-
ses, Cox regression models ( 36 ) were used to estimate the associa-
tion between the Ki67 index and breast cancer subtypes, with 
adjustment for with standard clinicopathological variables, includ-
ing age at diagnosis (as a continuous variable), histological grade 
(grade 3 vs grade 2 or 1), tumor size (>2 vs  ≥ 2 cm), lymphovascular 
invasion (positive vs negative), and number of positive axillary 
lymph nodes as a percentage of the total numbers examined 
(coded in three categories, in which 0% – 25% was compared with 
0%, and >25% was compared with 0%). We classiﬁ ed patients 
with breast cancer in the British Columbia population by using 
the percentage of positive lymph nodes as a continuous variable in 
the Cox model because this variable was shown to be more prog-
nostic than a categorical variable of one to three positive lymph 
nodes vs four or more than positive lymph nodes (37 ). Only 
patients with information for all the covariates were included in 
the Cox regression analyses. Smoothed plots of weighted 
Schoenfeld residuals were used to test proportional hazard 
assumptions ( 38 ), and no evidence that these assumptions were 
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invalid was observed. All statistical tests were two-sided, and 
 P values of less than .05 were considered statistically signiﬁ cant. 
The data were assembled to provide more than 80% power for test-
ing hypotheses regarding the biomarkers in all patients combined 
and for patient subgroups that were deﬁ ned by the adjuvant therapies 
received. 
 Results 
 Determination of Ki67 Index to Identify Luminal B Breast 
Cancers 
 Among the 357 breast tumors with qRT-PCR gene expression pro-
files ( Figure 1 ) and tumor subtypes as assigned by the 50-gene PAM50 
predictor ( 25 ), 101 (28%) were classified as luminal A, 69 (19%) 
luminal B, 62 (17%) HER2-enriched, 98 (28%) basal-like, and 27 
(8%) normal breast-like. From the gene expression profile data 
( 1 – 3 ), we expected that tumors classified as ER positive and HER2 
negative by immunohistochemistry would include a mixture of 
luminal A and luminal B subtypes that might be distinguished by 
Ki67 index. By linking the available immunohistochemical data 
with the expression profile assignments, we identified 84 hormone 
receptor – positive and HER2-negative tumors as luminal A and 60 
tumors as luminal B. 
 Ki67 index is a continuous variable, but a biologically and clini-
cally relevant cut point can be determined by the ROC method 
and a gene expression proﬁ le – deﬁ ned gold standard. Among the 
144 luminal A or B tumors in the training set, the best cutoff value 
for the immunohistochemically determined Ki67 index to distin-
guish luminal B was 13.25% ( Figure 2, A ). The sensitivity of the 
Ki67 index with this cutoff value was 72% (95% CI = 59% to 
82%), and the speciﬁ city was 77% (95% CI = 67% to 85%). 
Among these 144 tumors, 17 were considered borderline by virtue 
of having a less than 0.100 difference between Spearman rank cor-
relation coefﬁ cients for the luminal A and B centroids (meaning 
that the 50-gene proﬁ le correlated with luminal A and B types 
almost equally well). When we excluded these borderline tumors 
and restricted the ROC analysis to the 74 unambiguously luminal 
A and 53 unambiguously luminal B tumors, we still found that the 
best cutoff value for Ki67 immunohistochemistry data was 13.25%, 
with a sensitivity of 77% (95% CI = 64% to 87%) and a speciﬁ city 
of 78% (95% CI = 68% to 87%) ( Figure 2, B ). 
 Deﬁ ning a visually assessable cut point allows assignment of 
standard pathology breast cancer specimens into luminal A and B 
subtypes by use of immunohistochemical approaches. We selected 
a Ki67 index of 14% or more Ki67-positive tumor nuclei as the 
best cut point for human visual assessment. That is, we deﬁ ned the 
luminal A subtype as being ER and/or PR positive, HER2 nega-
tive, and Ki67 low (ie, a Ki67 index of <14%) and the luminal B 
subtype as being ER and/or PR positive, HER2 negative, and Ki67 
high (ie, a Ki67 index of  ≥ 14%). Although expression proﬁ ling also 
classiﬁ es ER-positive, HER2-positive tumors as luminal B, patients 
with HER2-positive breast cancer currently receive a different 
therapy regimen (that incorporates targeted anti-HER2 therapy) 
than patients with other luminal breast cancer subtypes. We there-
fore separated luminal tumors into three groups — luminal A, 
luminal B, and luminal – HER2 positive — in subsequent survival 
analyses. 
 Predicting Survival Among Hormone Receptor – Positive 
Breast Cancers With the Surrogate Immunopanel of ER, 
PR, HER2, and Ki67 
 When we used HER2 and Ki67 immunohistochemistry to sub-
type the 2598 hormone receptor – positive tumors in the BCCA 
series, we classified 1530 (59%, 95% CI = 57% to 61%) as luminal 
A, 846 (33%, 95% CI = 31% to 34%) as luminal B, and 222 (9%, 
95% CI = 7% to 10%) as luminal – HER2-positive tumors. In 
comparison with luminal A, both luminal B and luminal – HER2-
positive tumors ( Table 1 ) were statistically significantly associated 
with younger age at diagnosis, higher grade, larger tumor size, 
positive lymph node involvement, and lymphovascular invasion 
(all  P < .001). 
 Among the tumors from the 943 clinically low-risk patients in 
the BCCA series who were lymph node negative at diagnosis and 
did not receive adjuvant systemic therapy, the surrogate immuno-
histochemical panel classiﬁ ed 625 as luminal A, 263 as luminal B, 
and 55 as luminal – HER2-positive tumors. The 10-year relapse-
free survival was 78% (95% CI = 75% to 82%) for patients with 
luminal A tumors, 67% (95% CI = 61% to 73%) for those with 
luminal B tumors, and 64% (95% CI = 52% to 78%) for those 
with luminal – HER2-positive tumors ( Figure 3, A ) (for luminal B 
vs luminal A survival, log-rank  P < .001; and for luminal – HER2-
positive tumors vs luminal A survival, log-rank  P = .02). The 10-year 
breast cancer – speciﬁ c survival was 92% (95% CI = 90% to 94%) 
for those with luminal A tumors, 79% (95% CI = 74% to 85%) for 
those with luminal B tumors, and 78% (95% CI = 67% to 90%) 
for those with luminal – HER2-positive tumors ( Figure 3, B ) (for 
luminal B vs luminal A survival, log-rank  P < .001; and for luminal – 
HER2-positive tumors vs luminal A survival, log-rank  P < .001). In 
a multivariable Cox regression comparison ( Table 2 ), the luminal B 
subtype was associated with statistically signiﬁ cantly poorer relapse-
free survival (hazard ratio [HR] = 1.4, 95% CI = 1.1 to 1.9) and 
poorer breast cancer – speciﬁ c survival (HR = 1.8, 95% CI = 1.3 to 
2.6) than the luminal A subtype. In addition, the luminal – HER2-
positive subtype was associated with statistically signiﬁ cantly poorer 
relapse-free survival (HR = 1.6, 95% CI = 1.0 to 2.5) and breast 
cancer survival (HR = 2.1, 95% CI = 1.2 to 3.8) than the luminal A 
subtype ( Table 2 ). Ki67 and HER2 thus appear to provide addi-
tional prognostic information beyond clinical parameters currently 
in use as prognostic factors for the clinically low-risk patients with 
lymph node – negative and hormone receptor – positive breast 
cancer. 
 Among the 976 tumors from patients in the BCCA cohort 
treated with tamoxifen as their only adjuvant systemic therapy, 
we identiﬁ ed 584 as luminal A, 303 as luminal B, and 89 as 
luminal – HER2 positive by use of the surrogate immunopanel. 
The 10-year relapse-free survival was 70% (95% CI = 66% to 
74%) for patients with luminal A tumors, 53% (95% CI = 47% 
to 59%) for patients with luminal B tumors, and 51% (95% CI = 
41% to 63%) for patients with luminal – HER2-positive tumors 
( Figure 4, A ) (for luminal B vs luminal A and luminal – HER2-
positive tumors vs luminal A, all log-rank  P < .001). The 10-year 
breast cancer – speciﬁ c survival was 79% (95% CI = 76% to 83%) 
for patients with luminal A tumors, 64% (95% CI = 59% to 
70%) for patients with luminal B tumors, and 57% (95% CI = 
47% to 69%) for patients with luminal – HER2-positive tumors 
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 Figure 1 .  Flow diagram of the strategy for devel-
opment and implementation of a breast cancer 
specimen classiﬁ er.  A ) Development with breast 
cancer specimens from the University of British 
Columbia and Washington University at St Louis 
(ie, the UBC-WashU series).  B ) Implementation or 
application to breast cancer specimens from the 
British Columbia Cancer Agency (ie, the BCCA 
series). ER = estrogen receptor; qRT-PCR = quan-
titative reverse transcription – polymerase chain 
reaction; IHC = immunohistochemistry; PR = 
progesterone receptor. 
Breast cancer samples from
Washington University at St Louis
n = 78
Node positive [n = 40 (51%)]
Grade 3 [n = 61 (78%)]
Tumor size > 2cm [n = 47 (60%)]
ER* positive [n = 22 (28%)]
Tumors subjected to  
(1)      50-genes qRT-PCR* profile
(2)      IHC* for ER*, PR*, HER2, Ki67
Breast cancer samples from
University of British Columbia
n = 279
Node positive [n = 97 (35%)]
Grade 3 [n = 72 (26%)]
Tumor size > 2cm [n = 153 (55%)]
ER* positive [n = 199 (71%)]
Tumors subjected to 
(1)     50-genes qRT-PCR* profile
(2)     IHC* for ER*, PR*, HER2, Ki67
UBC-WashU series
n = 357
Luminal A [n = 101 (28%)]
Luminal B [n = 69 (19%)]
HER2-enriched [n = 62 (17%)]
Basal [n = 98 (27%)]
Normal-like [n = 27 (8%)]
+
50-gene PAM50 classifier to
assign breast cancer
subtypes according to gene
expression profile   
Tumors that are both (1) Luminal A or Luminal B tumors by genes expression profile, AND
(2) Hormone receptor positive and HER2 negative by IHC
n = 144 (40%) 
Define the best cutoff of Ki-67 IHC labeling index to differentiate Luminal A from Luminal B tumors
Merged both
data sets
(A) Development of immunopanel in the UBC-WashU series (n = 357)
BCCA breast cancer series
n = 4046
Node positive [n = 1701 (42%)]
Grade 3 [n = 2069 (51%)]
Tumor size > 2cm [n = 1916 (47%)]
ER and/or PR positive tumors
n = 2598
Node positive [n = 1118 (43%)]
Grade 3 [n = 1144 (44%)]
Tumor size > 2cm [n = 1161 (45%)] 
Defined as
(1) Luminal A (HER2 negative and Ki-67 low) [n = 1530 (59%)]
(2) Luminal/HER2+ (HER2 positive) [n = 222 (9%)]
(3) Luminal B (HER2 positive, Ki-67 high) [n = 846 (33%)]
(B) Application of immunopanel in the BCCA series (n = 4046)
Determine the prognostic value of luminal breast cancer subtypes 
( Figure 4, B ) (for luminal B vs luminal A and luminal – HER2-
positive tumors vs luminal A, all log-rank  P < .001). In the mul-
tivariable Cox regression analyses, the luminal B (for relapse-free 
survival, HR of recurrence = 1.5, 95% CI = 1.3 to 2.0,  P < .001) 
and luminal – HER2-positive (for relapse-free survival, HR of 
recurrence = 1.6, 95% CI = 1.1 to 2.3,  P = .02) subtypes were 
associated with more than 1.5 times increased risk for relapse 
and/or death from breast cancer compared with the luminal A 
subtype ( Table 3 ). These ﬁ ndings remained statistically signiﬁ -
cant among patients with lymph node – negative or lymph node – 
positive breast cancer ( Figure 4, C – F and  Table 3 ; the number of 
events among patients with luminal – HER2-positive, lymph 
node – negative tumors was too small for accurate interpretation 
of this subset). 
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 Figure 2 .  The x and y axes of ROC curve are true positive rate and 
false positive rate respectively. True positive rate equals to sensitiv-
ity and false positive rate is 1-speciﬁ city. Establishment of Ki67 cut 
point. True positive rate equals to sensitivity and false positive rate 
is 1-speciﬁ city.  A ) ROC analysis of 144 luminal A and B tumors with 
Ki67 IHC data to identify luminal B tumors as deﬁ ned by a 50-gene clas-
siﬁ er. Gene expression data for the classiﬁ er were obtained by quantita-
tive reverse transcription – polymerase chain reaction . The selected best 
cut point for the Ki67 index was 13.25%.  B ) ROC analysis that was 
conﬁ ned to 127 luminal A and B tumors with Spearman rank correla-
tion coefﬁ cients of more than 0.1. CI = conﬁ dence interval; ROC = 
receiver operating characteristic; IHS = immunohistochemistry. 
 Among the 196 patients with hormone receptor – positive tumors 
who were treated with both adjuvant tamoxifen and chemotherapy 
in the BCCA cohort, 124 were treated with anthracycline-based 
regimens of doxorubicin and cyclophosphamide or of ﬂ uorouracil, 
doxorubicin, and cyclophosphamide, and 72 were treated with non-
anthracycline – based regimens of cyclophosphamide, methotrexate, 
and ﬂ uorouracil. The majority of these tumors were high grade and 
larger than 2 cm in diameter, and patients had positive lymphovas-
cular invasion and/or more than 25% positive axillary lymph nodes 
of the total examined at primary surgery. No statistically signiﬁ cant 
differences were found in the clinicopathological parameters or 
breast cancer subtype frequencies between cohorts treated with the 
anthracycline-based regimens of doxorubicin and cyclophosph-
amide or of ﬂ uorouracil, doxorubicin, and cyclophosphamide, and 
those treated with non-anthracycline – based regimens of cyclophos-
phamide, methotrexate, and ﬂ uorouracil ( Table 4 ). When we used 
the immunohistochemical surrogate deﬁ nition (ie, ER, PR, HER2, 
and Ki67) to classify these 196 hormone receptor – positive tumors, 
we found that 87 were luminal A, 84 were luminal B, and 25 were 
luminal – HER2-positive tumors from patients who received com-
bined adjuvant treatment. The 10-year relapse-free survival was 
69% (95% CI = 59% to 79%) for patients with luminal A tumors, 
51% (95% CI = 42% to 63%) for those with luminal B tumors, and 
42% (95% CI = 26% to 67%) for those with luminal – HER2-posi-
tive tumors ( Figure 5, A ) (for luminal B vs luminal A, log-rank  P = 
.007; and for luminal – HER2-positive tumors vs luminal A, log-rank 
 P = .006). The 10-year breast cancer – speciﬁ c survival was 78% (95% 
CI = 69% to 87%) for those with luminal A tumors, 58% (95% CI = 
48% to 70%) for those with luminal B tumors, and 44% (95% 
CI = 28% to 70%) for those with luminal – HER2-positive tumors 
( Figure 5, B ) (for luminal B vs luminal A, log-rank  P = .014; and for 
luminal – HER2-positive tumors vs luminal A, log-rank  P = .001). In 
multivariable Cox regression analyses, breast cancer subtypes 
retained independent association with survival ( Table 3 ). Both lumi-
nal B (for relapse-free survival, HR of recurrence = 2.03, 95% CI = 
1.15 to 3.58,  P = .015) and luminal – HER2-positive (for relapse-free 
survival, HR of recurrence = 2.65, 95% CI = 1.23 to 5.71,  P = .013) 
tumors were associated with more than twofold increased risk for 
recurrence and death from breast cancer, compared with luminal A 
tumors. In this subset, breast cancer subtype was the only variable 
(other than >25% lymph node involvement) that was statistically 
signiﬁ cantly associated with breast cancer outcome. 
 Discussion 
 In this study, we develop an easily applied immunohistochemical 
surrogate for gene expression profile – defined luminal subtypes of 
breast cancer. We demonstrated that biological subtyping by use 
of this immunohistochemical surrogate panel of four biomarkers 
(ie, ER, PR, HER2, and Ki67) had statistically significant value 
that was independent of standard clinicopathological parameters 
(including age at diagnosis, tumor size, grade, lymphovascular 
invasion, and axillary lymph node status) in identifying high-risk 
women with hormone receptor – positive breast cancer in the set-
tings of no adjuvant systemic therapy, adjuvant tamoxifen, and 
combined adjuvant tamoxifen and chemotherapy. 
 Gene expression proﬁ ling studies have consistently revealed 
biologically distinct breast cancer subtypes with different progno-
ses ( 39 ). Luminal B breast cancers are a clinically important sub-
group associated with poor outcome in both the presence and the 
absence of systemic adjuvant therapy. By use of two independent 
cohorts of invasive breast carcinomas, our study is, to our knowl-
edge, the ﬁ rst to develop a four-marker surrogate immuno-
histochemistry panel, including ER, PR, HER2, and Ki67, to 
distinguish the luminal B subtype from the luminal A subtype. We 
developed the immunopanel against a gold standard deﬁ nition for 
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 Table 1 .  Clinicopathological characteristics of breast cancers used in this study * 
 Characteristic
UBC-WashU series
Total BCCA 
series Luminal tumors in BCCA series 
 Training set (n = 357), 
No. of patients (%)
Validation set 
(n = 4046), No. 
of patients (%)
No. of luminal 
A (%) (n = 1530)
No. of luminal 
B (%) (n = 846)
No. of luminal/HER2+ 
(%) (n = 222)
Total No. 
(n = 2598) 
 Age at diagnosis, y 
  ≤ 40 34 (10) 380 (9) 82 (5.4) 82 (9.7) 21 (9.5) 185 
  40 – 49 73 (20) 767 (19) 261 (17.1) 175 (20.7) 49 (22.1) 485 
  50 – 65 119 (33) 1435 (36) 566 (37.0) 275 (32.5) 78 (35.1) 919 
  >65 124 (35) 1464 (36) 621 (40.6) 314 (37.1) 74 (33.3) 1099 
  Unknown 7 (2) 0 (0) 0 (0) 0 (0) 0 (0) 0 
 Menstrual status at referral 
  Premenopausal  — 1188 (29) 363 (23.7) 281 (33.2) 66 (29.7) 710 
  Postmenopausal  — 2761 (68) 1139 (74.4) 548 (64.8) 145 (65.3) 1832 
  Pregnant  — 2 (0.1) 0 (0) 0 (0) 1 (0.5) 1 
  Unknown  — 95 (2) 28 (1.8) 17 (2.0) 10 (4.5) 55 
 Histology 
  Ductal 322 (90) 3661 (91) 1390 (90.8) 781 (92.3) 216 (97.3) 2387 
  Lobular 27 (8) 308 (8) 133 (8.7) 59 (7.0) 5 (2.3) 197 
  Other 6 (2) 77 (2) 7 (0.5) 6 (0.7) 1 (0.5) 14 
  Unknown 2 (0.6) 0 (0) 0 (0) 0 (0) 0 0 
 Grade 
  1 45 (13) 211 (5) 925 (60.5) † 350 (41.4) † 60 (27.0) † 1335 † 
  2 171 (48) 1582 (39)     
  3 133 (37) 2069 (51) 521 (34.1) 468 (55.3) 155 (69.8) 1144 
  Unknown 8 (2) 184 (5) 84 (5.5) 28 (3.3) 7 (3.2) 119 
 Tumor size, cm 
  ≤ 2 139 (39) 2093 (52) 943 (61.6) 384 (45.4) 90 (40.5) 1417 
  2 – 5 170 (48) 1697 (42) 580 (37.9) ‡ 450 (53.2) ‡ 131 (59.0) 1161 ‡ 
  >5 30 (8) 219 (5)     
  Unknown 18 (5) 37 (1) 7 (0.5) 12 (1.4) 1 (0.5) 20 
 Lymph node status 
  Negative 183 (51) 2161 (53) 844 (55.2) 422 (49.9) 90 (40.5) 1356 
  Positive 137 (38) 1701 (42)     
   1 – 3 lymph nodes   436 (28.5) 244 (28.8) 64 (28.8) 744 
   ≥ 4 lymph nodes   180 (11.8) 140 (16.5) 54 (24.3) 374 
  Unknown 37 (10) 184 (5) 70 (4.6) 40 (4.7) 14 (6.3) 124 
 Lymphovascular invasion 
  Positive  — 1750 (43) 590 (38.6) 423 (50.0) 133 (59.9) 1146 
  Negative  — 2120 (52) 874 (57.1) 385 (45.5) 84 (37.8) 1343 
  Unknown  — 176 (4) 66 (4.3) 38 (4.5) 5 (2.3) 109 
 ER status 
  Positive 221 (62) 2791 (69) 1480 (96.7) 823 (97.3) 204 (91.9) 2507 
  Negative 109 (31) 1224 (30) 47 (3.1) 23 (2.7) 18 (8.1) 88 
  Uninterpretable 27 (8) 31 (1) 3 (.2) 0 (0) 0 (0) 3 
 PR status 
  Positive 137 (40) 1846 (46) 1040 (68) 522 (61.7) 108 (48.6) 1670 
  Negative 142 (38) 1759 (43) 389 (25.4) 275 (32.5) 105 (47.3) 769 
  Uninterpretable 78 (22) 441 (11) 101 (6.6) 49 (5.8) 9 (4.1) 159 
 HER2 status 
  Positive 35 (10) 507 (13) 0 (0) 0 (0) 222 (100) 222 
  Negative 277 (78) 3360 (83) 1530 (100) 846 (100) 0 (0) 2376 
  Uninterpretable 45 (13) 179 (4) 0 (0) 0 (0) 0 (0) 0 
 Local therapy 
  No breast surgery  — 60 (2) 25 (1.6) 11 (1.3) 2 (0.9) 38 
  Mastectomy + RT  — 631 (16) 196 (12.8) 129 (15.2) 47 (21.2) 372 
  Mastectomy alone  — 1557 (39) 589 (38.5) 341 (40.3) 92 (41.4) 1022 
  Lumpectomy alone  — 135 (3) 54 (3.5) 31 (3.7) 4 (1.8) 89 
  Lumpectomy + RT  — 1663 (41) 666 (43.5) 334 (39.5) 77 (34.7) 1077 
(Table continues)
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 Figure 3 .  Univariate survival by breast cancer subtype among 943 patients with lymph node – negative, hormone receptor – positive breast cancer 
who received no adjuvant systemic therapy.  A ) Relapse-free survival.  B ) Breast cancer – speciﬁ c survival. CI = conﬁ dence interval. 
 Characteristic
UBC-WashU series
Total BCCA 
series Luminal tumors in BCCA series 
 Training set (n = 357), 
No. of patients (%)
Validation set 
(n = 4046), No. 
of patients (%)
No. of luminal 
A (%) (n = 1530)
No. of luminal 
B (%) (n = 846)
No. of luminal/HER2+ 
(%) (n = 222)
Total No. 
(n = 2598) 
 Adjuvant systemic therapy 
  None 128 (36) 1689 (42) 672 (43.9) 287 (33.9) 64 (28.8) 1023 
  HT only 82 (23)      
   Tam only  1305 (32) 542 (38.2) 303 (35.8) 89 (40.1) 976 
   Ovarian ablation or 
  HT other than Tam
 7 (0.2) 2 (0.1) 2 (0.2) 0 (0) 4 
  Chemotherapy only 65 (18)      
   AC  148 (4) 23 (1.5) 31 (3.7) 6 (2.7) 60 
   CMF  429 (11) 143 (9.3) 96 (11.3) 27 (12.2) 266 
   FAC  92 (2) 12 (0.8) 25 (3.0) 7 (3.2) 44 
   Other  70 (2) 7 (0.5) 13 (1.5) 4 (1.9) 24 
  Combination therapy 78 (22)      
   AC + Tam  125 (3) 39 (2.5) 37 (4.4) 11 (5.0) 87 
   CMF + Tam  39 (1) 15 (1.0) 13 (1.5) 2 (0.9) 30 
   FAC + Tam  68 (2) 13 (0.8) 16 (1.9) 8 (3.6) 37 
  Chemotherapy 
  (other) + Tam
 69 (2) 20 (1.3) 18 (2.1) 4 (1.8) 42 
   Ovarian ablation or 
  HT + chemotherapy
 5 (0.1) 0 (0) 5 (0.6) 0 (0) 5 
  Unknown 4 (1) 0 (0) 0 (0) 0 (0) 0 (0) 0 
 *  UBC-WashU = University of British Columbia and Washington University at St Louis series; BCCA = British Columbia Cancer Agency series; RT = radiation 
therapy; ER = estrogen receptor; PR = progesterone receptor; Tam = tamoxifen; HT = hormone therapy; AC = doxorubicin and cyclophosphamide; 
CMF = cyclophosphamide, methotrexate, and fluorouracil; FAC = 5-fluorouracil, doxorubicin, and cyclophosphamide;  — = not available. 
 †  Grade 1 or 2 tumors combined for   2 test. 
 ‡  Tumor size more than 2 cm used for   2 test. 
Table 1 (continued).
tumor subtype that used results from gene expression proﬁ ling and 
demonstrated clinically signiﬁ cant associations with breast cancer 
relapse and survival. 
 The luminal B subtype is characterized by having increased 
expression of HER2-associated genes (ie,  ERBB2 and  GRB7 ) and a 
cell proliferation signature that includes the expression of  MKI67 , 
 CCNB1 , and  MYBL2 , which have been associated with tamoxifen 
resistance ( 16 , 40 ). Efﬁ cient clinical identiﬁ cation of luminal B 
breast cancers would isolate a poor prognosis subgroup that could 
likely beneﬁ t from additional systemic therapy from among other-
wise good prognosis, hormone receptor – positive tumors. As sug-
gested from gene expression proﬁ ling, coexpression of HER2 and 
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 Table 2 .  Association of patient and tumor characteristics with relapse-free survival and breast cancer – specific survival among 
883 patients with lymph node – negative, hormone receptor – positive breast cancer with complete data for covariates and who 
did not receive any adjuvant systemic therapy * 
 Characteristic and comparison
Relapse-free survival (n = 883) 
Breast cancer – specific 
survival (n = 879) 
 HR (95% CI)  P value † HR (95% CI)  P value † 
 Age at diagnosis ‡ 1.00 (0.99 to 1.01) .43 1.01 (0.99 to 1.02) .30 
 Grade (3 vs 2 or 1) 1.10 (0.84 to 1.44) .50 1.24 (0.88 to 1.75) .22 
 Tumor size (>2 cm vs  ≤ 2 cm) 1.43 (1.09 to 1.86) .010 1.59 (1.14 to 2.23) .007 
 LVI (positive vs negative) 1.49 (1.04 to 2.13) .031 1.72 (1.11 to 2.66) .015 
 Breast cancer subtypes 
  Luminal B vs luminal A 1.43 (1.08 to 1.90) .013 1.84 (1.28 to 2.63) .001 
  Luminal/HER2+ vs luminal A 1.57 (0.97 to 2.54) .066 2.08 (1.15 to 3.76) .016 
 *  Multivariable Cox proportional hazards regression analyses were used to estimate the adjusted HRs for the breast cancer subtypes. HR = hazard ratio; 
CI = confidence interval; LVI = lymphovascular invasion. 
 †  All Wald statistical tests were two-sided. 
 ‡  Age is in years. 
ER and/or PR can identify some luminal B tumors (ie, the luminal – 
HER2-positive group). However, only approximately 30% of 
luminal B tumors are HER2 positive, indicating that this clinical 
marker alone is not sensitive enough to identify most luminal B 
breast cancers. In this study, we categorized such tumors as lumi-
nal – HER2 positive because they require a distinct treatment 
approach involving HER2-targeted therapy (eg, trastuzumab). 
However, from a biological perspective (ie, in terms of their gene 
expression proﬁ le), these tumors belong to the luminal B subtype. 
 Ki67 is a well-established cell proliferation marker in cancer 
and an excellent candidate biomarker for luminal B tumors. Two 
recent meta-analyses have reported a statistically signiﬁ cant asso-
ciation between high Ki67 expression and increased risk of breast 
cancer relapse and death ( 12 , 41 ). However, assessment of Ki67 has 
been a matter of controversy because some studies have used 10% 
( 42 , 43 ) or 20% ( 44 , 45 ) cut points, whereas others dichotomized 
around the mean ( 46 ) or median ( 30 , 47 ) value. Our study is the 
ﬁ rst to apply quantitative Ki67 visual immunohistochemistry 
scores to breast cancer biological subtypes that were classiﬁ ed by 
gene expression proﬁ ling. An advantage of this approach is that the 
optimal threshold of Ki67 immunohistochemistry (in this case 
14%) was determined against an important distinction in the 
underlying biology of breast cancer rather than against clinical 
outcome or the mean or median value of the Ki67 index in the 
study population. By this approach, the cut point will more likely 
be directly applicable in other cohorts of patients with different 
treatment regimens and risk distributions. Although gene expres-
sion proﬁ ling remains the most sensitive method, we have demon-
strated that Ki67 can be added concurrently to the standard 
biomarker panel of ER, PR, and HER2 to identify additional lumi-
nal B tumors that would not be identiﬁ ed by these three markers. 
The addition of epidermal growth factor receptor and cytokeratin 
5/6 to this panel allows identiﬁ cation of the basal-like subtype of 
breast cancer ( 20 , 48 ). 
 We evaluated the prognostic value of our luminal B immuno-
histochemistry panel using an independent, regional population-
based cohort of 4046 patients who were originally diagnosed with 
breast cancer between January 1, 1986, and September 30, 1992. 
These patients received adjuvant therapy according to guidelines 
developed and disseminated by the British Columbia Cancer 
Agency ( 24 ). In general, adjuvant systemic treatment was less 
aggressive than in contemporary practice, with consequent higher 
event rates. We demonstrated the prognostic value of our luminal 
B deﬁ nition within homogeneously treated patient subsets. Among 
patients with hormone receptor – positive tumors who received no 
adjuvant systemic treatment, luminal B and luminal – HER2-positive 
tumors were associated with increased risk of breast cancer relapse 
and death. In contemporary practice, almost all patients with hor-
mone receptor – positive breast cancer are treated with hormonal 
therapy (tamoxifen or aromatase inhibitors), and in this study, 
luminal B and luminal – HER2-positive tumors were associated 
with increased risk of breast cancer relapse and death in the sub-
group receiving adjuvant tamoxifen, in comparison with the more 
common luminal A subtype. 
 In multivariable analysis, the luminal B and luminal – HER2-
positive subtypes provided statistically signiﬁ cant prognostic value 
beyond current standard clinicopathological parameters. The Cox 
regression models included tumor size, age at diagnosis, grade, 
lymph node involvement, and lymphovascular invasion, which 
include the compulsory variables for calculation of the Nottingham 
Prognostic Index ( 49 ) and Adjuvant! Online, a computer software 
program that predicts breast cancer outcomes by use of SEER data 
and clinical trial meta-analyses to guide treatment decisions in 
clinical practice ( 50 ). Indeed, almost half of our patient cohort was 
included in an earlier study conﬁ rming that in the British Columbia 
population, Adjuvant! predictions are associated with observed 
outcomes ( 51 ), providing support that the conclusions in this study 
can be extended to other North American and UK populations. 
Luminal B status as deﬁ ned by Ki67 labeling retained independent 
prognostic value in patients with lymph node – negative or lymph 
node – positive, hormone receptor – positive breast cancer who were 
treated with adjuvant tamoxifen. The recurrence score, a qRT-
PCR – based measure of risk of breast cancer recurrence, is cur-
rently an available diagnostic test to predict distant recurrence for 
ER-positive breast cancers in patients with negative axillary lymph 
nodes who are treated with adjuvant tamoxifen ( 19 ). This score 
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 Figure 4 .  Univariate survival by breast cancer subtype among 
976 patients with hormone receptor–positive breast cancer who received 
tamoxifen as their sole adjuvant systemic therapy.  A ) Relapse-free sur-
vival among all 976 patients.  B ) Breast cancer–speciﬁ c survival among all 
974 patients (two patients with unknown cause of death were excluded). 
C) Relapse-free survival among 287 patients with lymph node–negative 
disease.  D ) Breast cancer–speciﬁ c survival among 287 patients 
with lymph node–negative disease.  E ) Relapse-free survival among 
627 patients with lymph node–positive disease.  F ) Breast cancer–speciﬁ c 
survival among 625 patients with lymph node–positive disease (two 
patients with unknown cause of death were excluded). CI = conﬁ dence 
interval. 
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 Table 3 .  Association of patient and tumor characteristics with relapse-free survival and breast cancer – specific survival among 
828 hormone receptor – positive patients with complete data for covariates and who received tamoxifen as their sole adjuvant systemic 
therapy and among 167 patients with hormone receptor – positive tumors with complete data for all the covariates and who received 
both tamoxifen and chemotherapy as adjuvant systemic therapies * 
 Characteristic and comparison
Relapse-free survival Breast cancer-specific survival 
 HR (95% CI)  P value † HR (95% CI)  P value † 
 Hormone receptor – positive patients 
   who received only tamoxifen as 
   adjuvant therapy 
  Total group ‡ 
   Age at diagnosis § 0.99 (0.98 to 1.00) .090 1.00 (0.98 to 1.02) .95 
   Grade (3 vs 2 or 1) 1.33 (1.06 to 1.68) .016 1.35 (1.04 to 1.75) .023 
   Tumor size (> 2 vs  ≤ 2 cm) 1.56 (1.23 to 1.97) <.001 1.64 (1.26 to 2.13) <.001 
   LVI (positive vs negative) 1.18 (0.91 to 1.51) .21 1.02 (0.78 to 1.34) .88 
   Positive axillary lymph nodes, 
    % of total examined 
    0 – 25 vs 0 1.91 (1.40 to 2.61) <.001 1.69 (1.19 to 2.40) .004 
    > 25 vs 0 3.24 (2.38 to 4.42) <.001 3.26 (2.32 to 4.57) <.001 
  Breast cancer subtypes 
   Luminal B vs luminal A 1.59 (1.25 to 2.03) <.001 1.60 (1.22 to 2.10) <.001 
   Luminal/HER2+ vs luminal A 1.56 (1.09 to 2.25) .016 1.77 (1.20 to 2.62) .004 
  Group with lymph node – negative 
    disease (n = 267) 
   Age at diagnosis § 1.02 (0.99 to 1.05) .28 1.03 (1.00 to 1.07) .06 
   Grade (3 vs 2 or 1) 1.63 (0.96 to 2.76) .070 1.25 (0.70 to 2.22) .45 
   Tumor size (> 2 vs  ≤ 2 cm) 1.42 (0.83 to 2.41) .20 1.54 (0.85 to 2.78) .16 
   LVI (positive vs negative) 0.87 (0.51 to 1.46) .59 0.90 (0.51 to 1.61) .73 
  Breast cancer subtypes 
   Luminal B vs luminal A 2.14 (1.24 to 3.67) .006 2.22 (1.22 to 4.04) .009 
   Luminal/HER2+ vs luminal A 1.07 (0.36 to 3.16) .90 1.04 (0.30 to 3.60) .95 
  Group with lymph node – positive disease ║ 
   Age at diagnosis § 0.99 (0.97 to 1.00) .062 1.00 (0.98 to 1.01) .71 
   Grade (3 vs 2 or 1) 1.32 (1.02 to 1.70) .037 1.46 (1.09 to 1.95) .011 
   Tumor size (> 2 vs  ≤ 2 cm) 1.67 (1.28 to 2.16) <.001 1.75 (1.30 to 2.34) <.001 
   LVI (positive vs negative) 1.33 (0.99 to 1.79) .057 1.09 (0.80 to 1.51) .56 
  Breast cancer subtypes 
   Luminal B vs luminal A 1.50 (1.14 to 1.97) .004 1.49 (1.09 to 2.03) .013 
   Luminal/HER2+ vs luminal A 1.78 (1.21 to 2.62) .004 2.03 (1.34 to 3.07) <.001 
 Hormone receptor – positive patients who 
   received both tamoxifen and 
   chemotherapy 
  Total group ¶ 
   Age at diagnosis § 0.97 (0.94 to 1.00) .046 0.98 (0.94 to 1.01) .13 
   Grade (3 vs 2 or 1) 1.19 (0.70 to 2.03) .52 0.94 (0.54 to 1.62) .82 
   Tumor size (> 2 vs  ≤ 2 cm) 1.00 (0.57 to 1.76) 1.00 1.54 (0.82 to 2.90) .18 
   LVI (positive vs negative) 1.05 (0.59 to 1.87) .86 1.00 (0.54 to 1.84) .99 
   % of positive axillary lymph nodes 
    over total examined 
    0 – 25 vs 0 1.54 (0.70 to 3.40) .29 2.11 (0.83 to 5.34) .12 
    > 25 vs 0 2.04 (0.96 to 4.30) .062 3.11 (1.31 to 7.39) .010 
  Breast cancer subtypes 
  Luminal B vs luminal A 2.03 (1.15 to 3.58) .015 1.92 (1.05 to 3.52) .034 
  Luminal – HER2+ vs luminal A 2.65 (1.23 to 5.71) .013 3.73 (1.70 to 8.16) .001 
 *  Multivariable Cox proportional hazards regression analyses were used to estimate the adjusted HRs of breast cancer subtypes. HR = hazard ratio; 
CI = confidence interval; LVI = lymphovascular invasion. 
 †  All Wald statistical tests were two-sided. 
 ‡  In the total group, data from 828 patients were available for relapse-free survival and data from 826 patients were available for breast cancer – specific survival. 
 §  Age is in years. 
 ║  In this group, data from 561 patients were available for relapse-free survival and data from 559 patients were available for breast cancer – specific survival. 
 ¶  The total group had 167 patients with complete data for all the covariates and who received both tamoxifen and chemotherapy (doxorubicin and cyclophosph-
amide; fluorouracil, doxorubicin, and cyclophosphamide; or cyclophosphamide, methotrexate, and fluorouracil) as adjuvant systemic therapies. Data from all 
167 patients were available for both relapse-free survival and breast cancer – specific survival. 
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 Table 4 .  Clinicopathological characteristics of 196 hormone receptor – positive patients who received both tamoxifen and chemotherapy 
as their adjuvant systemic therapy * 
 Characteristic
Tamoxifen + (AC or FAC) 
(n = 124), N (%)
Tamoxifen + CMF 
(n = 72), N (%) Total (n = 196)  P value † 
 Age, y 
  ≤ 40 12 (9.7) 13 (18.1) 25
.094 
  40 – 49 50 (40.3) 18 (25.0) 68 
  50 – 65 58 (46.8) 37 (51.4) 95 
  >65 4 (3.2) 4 (5.6) 8 
 Tumor size, cm 
  ≤ 2 44 (36.7) 16 (22.5) 60
.053 
  >2 76 (63.3) 55 (77.5) 131 
 Grade 
  1 or 2 60 (50.0) 35 (51.5) 95
.88 
  3 60 (50.0) 33 (48.5) 93 
 Lymphovascular invasion 
  Negative 36 (30.8) 25 (37.3) 61
.42 
  Positive 81 (69.2) 42 (62.7) 123 
 % of positive axillary lymph nodes/total 
   examined lymph nodes 
  0 25 (20.7) 6 (9.2) 31
.067   0 – 25 40 (33.1) 19 (29.2) 59 
  >25 56 (46.3) 40 (61.5) 96 
 Breast cancer subtypes 
  Luminal A 52 (41.9) 35 (48.6) 87
.332   Luminal B 53 (42.7) 31 (43.1) 84 
  Luminal – HER2+ 19 (15.3) 6 (8.3) 25 
 *  AC = doxorubicin and cyclophosphamide; FAC = fluorouracil, doxorubicin, and cyclophosphamide; CMF = cyclophosphamide, methotrexate, and fluorouracil. 
 †  All Wald statistical tests were two-sided. 
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 Figure 5 .  Univariate survival by breast cancer subtype among 196 patients with hormone receptor – positive breast cancer who were treated with 
both tamoxifen and chemotherapy (doxorubicin and cyclophosphamide; ﬂ uorouracil, doxorubicin, and cyclophosphamide; or cyclophosphamide, 
methotrexate, and ﬂ uorouracil) as adjuvant systemic treatments.  A ) Relapse-free survival.  B ) Breast cancer – speciﬁ c survival. CI  = conﬁ dence 
interval. 
uses the expression of 16 genes, weighted heavily on  MKI67 and 
other proliferation-associated genes, to calculate a risk score. This 
recurrence score assay has not been applied to the BCCA series of 
tumors, which limits our capacity to do a head-to-head comparison 
between our immunopanel and this qRT-PCR assay (the cost of 
which is approximately 10-fold higher per tumor). However, Fan 
et al. ( 39 ) have shown that breast cancer subtype as determined by 
gene expression proﬁ ling and the recurrence score have statistically 
signiﬁ cant agreement in outcome predictions. This result indicates 
that among patients with lymph node – negative, ER-positive dis-
ease who were treated with adjuvant tamoxifen, high recurrence 
scores appear to track largely with luminal B cancers. 
 The association between the luminal B subtype and response to 
adjuvant systemic chemotherapy has yet to be fully elucidated. A 
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meta-analysis of 1521 patients with endocrine-responsive tumors 
enrolled in two randomized trials of adjuvant chemoendocrine 
therapy reported that Ki67 expression as a single marker was not 
associated with resistance or beneﬁ t from chemotherapy, beyond 
the beneﬁ t incurred with hormonal therapy alone ( 30 ). The che-
motherapy regimen used in these two trials was cyclophosphamide, 
methotrexate, and ﬂ uorouracil, and the median value — 19% — was 
the cut point for the Ki67 index. In contrast, we assessed the Ki67 
index only in the context of hormone receptor – positive, HER2-
negative tumors and used a cut point of 14%. We found that the 
Ki67 index and HER2 expression could be used to stratify the risk 
for breast cancer relapse and death among patients with hormone 
receptor – positive breast cancer who were treated with both tamox-
ifen and chemotherapy as their adjuvant systemic therapy. 
 This study has several limitations. The main weaknesses of 
immunohistochemical approaches are limited technical reproduc-
ibility, subjective interpretation, and qualitative readouts ( 52 , 53 ). 
To facilitate analysis of sufﬁ ciently large cohorts of samples, the 
immunostaining panel was trained and validated on tissue microar-
rays, whereas clinical implementation would likely occur on whole 
sections. It is possible that Ki67 index may demonstrate focally 
higher areas on whole sections that can be appreciated on tissue 
microarrays, although tissue microarray results have repeatedly 
been demonstrated to show excellent agreement with whole sec-
tions ( 54 ), including in studies of breast cancer ( 55 ) and of Ki67 
( 56 ). The distinction between luminal A and luminal B tumors is 
somewhat difﬁ cult to achieve, and our panel has false-positive and 
false-negative rates of approximately 25% ( Figure 2 ). The need for 
long-term follow-up data necessitated the use of a historical cohort 
of old parafﬁ n blocks, which could potentially differ from recently 
ﬁ xed and processed prospective specimens. Treatment recommen-
dations at the time patients in this study were treated tended to be 
less aggressive than in contemporary practice, and treatment 
cohorts are not randomized in the population-based validation 
cohort. 
 Strengths of the study design include the use of large indepen-
dent cohorts to separate development of the immunopanel (against 
a gold standard of gene expression proﬁ ling) from its application 
to a large patient series for which information on clinical outcomes 
was available. Our subtype deﬁ nition was linked to breast cancer 
biology through a gene expression proﬁ ling approach in which 
tumor specimens were assigned to intrinsic breast cancer biologi-
cal subtypes, which were previously shown to be reproducible 
across patient populations and gene expression platforms ( 25 ), as 
opposed to being linked to an expression proﬁ le classiﬁ er opti-
mized against patient outcome (which can be problematic 
to extrapolate to other cohorts of patients who in general will 
have differences in risk proﬁ le and speciﬁ c treatment). The four-
biomarker immunopanel is economical, antibodies against the 
biomarkers are readily available, and equivalent tissue microarray 
approaches can be used with existing legacy specimens from clini-
cal trials to examine predictive values. Immunohistochemistry 
retains the advantage of assessing protein expression in the context 
of tumor morphology, can be applied to tiny core needle biopsy 
samples in clinical and research laboratories, and has a rapid 
turnaround time. Although we consider breast cancer molecular 
subtyping by gene expression proﬁ ling to be the gold standard, we 
nevertheless believe that there is an immediate need for a 
well-deﬁ ned and validated immunopanels for worldwide clinical 
diagnostic use. 
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